Literature DB >> 11679444

Dynamic pattern of disease-associated autoantibodies in siblings of children with type 1 diabetes: a population-based study.

K Savola1, E Läärä, P Vähäsalo, P Kulmala, H K Akerblom, M Knip.   

Abstract

To study the dynamics of disease-associated humoral immune responses, we analyzed autoantibodies to the IA-2 protein (IA-2A), glutamic acid decarboxylase (GADA), and insulin (IAA) and also islet cell antibodies (ICA) in a population-based, prospective, representative series of 710 siblings (<20 years of age) of children with type 1 diabetes. Positivity for single autoantibodies was observed in 8-13% of these siblings during an average follow-up of 4 years. The overall incidence rates per 1,000 years (number of cases/person-years in parentheses) for positive seroconversion of IA-2A were nine (19/2,123), followed by six (12/2,049) for GADA, 19 (40/2,111) for IAA, and 16 (31/1965) for ICA. Positive seroconversions seemed to be associated with a young age of the sibling, HLA DR3/DR4 heterozygosity, HLA identity, and a high initial number of detectable autoantibodies. The overall incidence rates per 1,000 years (number of cases/person-years in parentheses) for inverse seroconversion of IA-2A were 76 (12/157), followed by 42 (10/237) for GADA, 460 (32/70) for IAA, and 27 (9/331) for ICA. No consistent risk factor for inverse seroconversions was present, although seroconversions were most frequent in siblings with older age, male sex, HLA phenotypes other than DR3/DR4, a small family size, and no other autoantibodies detectable at seroconversion. Altogether, these observations indicate that beta-cell autoimmunity may be induced at any age in childhood and adolescence. HLA-conferred genetic disease susceptibility is a strong determinant of persistent beta-cell autoimmunity, but environmental factors may also contribute to such autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679444     DOI: 10.2337/diabetes.50.11.2625

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children.

Authors:  David Endesfelder; Michael Hagen; Christiane Winkler; Florian Haupt; Stephanie Zillmer; Annette Knopff; Ezio Bonifacio; Anette-G Ziegler; Wolfgang Zu Castell; Peter Achenbach
Journal:  Diabetologia       Date:  2016-07-11       Impact factor: 10.122

2.  Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes.

Authors:  I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-10-07       Impact factor: 10.122

Review 3.  Prediabetes in children: natural history, diagnosis, and preventive strategies.

Authors:  Petri Kulmala
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.

Authors:  I Vermeulen; I Weets; O Costa; M Asanghanwa; K Verhaeghen; K Decochez; J Ruige; K Casteels; J Wenzlau; J C Hutton; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

5.  Prediction of type 1 diabetes in the general population.

Authors:  Mikael Knip; Sari Korhonen; Petri Kulmala; Riitta Veijola; Antti Reunanen; Olli T Raitakari; Jorma Viikari; Hans K Akerblom
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 19.112

6.  Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes.

Authors:  I Truyen; J De Grijse; I Weets; L Kaufman; L Pipeleers; N Nanos; K Decochez; R Hilbrands; J-M Kaufman; B Keymeulen; C Mathieu; L Van Gaal; D G Pipeleers; F K Gorus
Journal:  Clin Exp Immunol       Date:  2007-05-22       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.